<IPO>SIHUAN PHARM Spins Off XUANZHUBIO-B (02575.HK) for IPO Starting Tdy; Entry Fee $5,858.5
SIHUAN PHARM (00460.HK) announced the details of the spin-off and IPO of XUANZHUBIO-B (02575.H...
SIHUAN PHARM (00460.HK) announced the details of the spin-off and IPO of XUANZHUBIO-B (02575.HK) in Hong Kong, planning to globally offer 67.3335 million H-shares, with 90% (approx. 60.6 million shares) for international placement and 10% (approx. 6.7335 million shares) for Hong Kong public offering.
The offer price per share is $11.6, aiming to raise approx. $781 million. The entry for a board lot of 500 shares is about $5,858.5.
The offering period starts today (6th), and will end this Friday (10th), with the listing anticipated on 15 October. CICC is its sole sponsor.
The company's IPO introduced private equity fund Denov Ruilang Phase XV as its cornerstone investor, subscribing to shares worth approx. $76.6 million, equivalent to about 6.603 million shares at the offer price, representing approx. 9.81% of the offer shares.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-10-03 16:25.)
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
